AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26265232
Drug: PH‐797804 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH‐797804 30 mg (oral)
Trial: 26265232
Drug: PF‐03715455 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐03715455 20 mg (inhaled)
Trial: 26265232
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 μg (inhaled)
Trial: 22081122
Drug: Traditional logopedic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional logopedic dysphagia treatment
Trial: 22081122
Drug: Traditional logopedic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional logopedic dysphagia treatment combined with NMES at sensor or motor level stimulation
Trial: 20815879
Drug: A-L dispersible
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-L dispersible tablet (cherry flavour)
Trial: 20815879
Drug: A-L dispersible
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-L dispersible tablet (80 mg artemether + 480 mg lumefantrine)
Trial: 20815879
Drug: A-L dispersible
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-L dispersible tablet
Trial: 17132823
Drug: GH (2
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH (2 mg daily)
Trial: 17132823
Drug: GH (2
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH (2 mg daily) + Acipimox (250 mg x 3 daily)
Trial: 9536401
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract/carboxymethyl-beta-1,3-glucan formulation applied 2X a day for 2 weeks
Trial: 2545773
Drug: Prior treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior treatment with pimozide
Trial: 24342196
Drug: Iron protein
RxNorm normalized name: Iron Protein Succinylate
DrugBank: Iron protein succinylate (DB11209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron protein succinylate (IPS) oral solution
Trial: 19494809
Drug: Fixed-dose MMF-treated
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose MMF-treated patients receiving tacrolimus with UGT1A9 -275T>A and/or -2152C>T polymorphism
Trial: 16461866
Drug: CM and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM and 300 mg/d of bupropion hydrochloride (CMB)
Trial: 15104569
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) with rFSH monotherapy
Trial: 15354458
Drug: 0.42% fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42% fluoride gel (8 applications at 3-month intervals)
Trial: 3556337
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg orally
Trial: 24599922
Drug: Biologics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics plus MTX
Trial: 19342020
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard protocol for endometrial preparation)
Trial: 14606933
Drug: Pimecrolimus (5-60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus (5-60mg single dose)
Trial: 14606933
Drug: Pimecrolimus (5-30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus (5-30mg multiple doses)
Trial: 1475622
Drug: Enteric-coated piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated piroxicam tablets (20 mg once daily for 2 weeks)
Trial: 1475622
Drug: Plain piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plain piroxicam tablets (20 mg once daily for 2 weeks)
Trial: 6383591
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy (intradermaIly with a Heaf gun and orally for 2 years)
Trial: 20054045
Drug: Mupirocin nasal
RxNorm normalized name: mupirocin Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin nasal ointment and chlorhexidine soap
Trial: 8548111
Drug: Parenteral antiarrhythmics
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antiarrhythmics
Trial: 1785181
Drug: Live recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live recombinant influenza vaccine type A (H1N1)
Trial: 1785181
Drug: Live recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live recombinant influenza vaccine type B
Trial: 1785181
Drug: Mono-vaccine (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-vaccine (either A or B)
Trial: 22148919
Drug: Achilles tendon
RxNorm normalized name: BOS TAURUS ACHILLES TENDON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achilles tendon vibration (1 h daily at 50 Hz for 14 days)
Trial: 15109191
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation with midazolam (mean total dose 7.9 mg +/- 4.2 SD)
Trial: 15109191
Drug: Operator-controlled sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operator-controlled sedation with midazolam (mean total dose 4.2 mg +/- 1.8 SD)
Trial: 18276017
Drug: Pharmacotherapy (PT)
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (PT)
Trial: 9925127
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation (8 mg elemental Fe, 5 mg elemental Zn, 333 microg retinol, 20 mg vitamin C 5 d/wk for 3 mo)
Trial: 9925127
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation (20 mg Fe, 17 mg Zn, 1700 microg retinol, 20 mg vitamin C once a week for 3 mo)
Trial: 2181223
Drug: ICRC anti-leprosy
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICRC anti-leprosy vaccine
Trial: 376132
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (procarbazine 100 mg/m2, Days 1‐‐10; vinblastine 5 mg/m2, Days 1 and 8; actinomycin D 0.5 mg/m2, Days 1 and 8)
Trial: 376132
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with MER (200 micrograms in five sites)
Trial: 376132
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with MER
Trial: 31887853
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg preoperatively
Trial: 31433708
Drug: Metacognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive therapy
Trial: 26094723
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg t.d.s for 12 weeks, along with prednisolone 40 mg o.d. tapered over 12 weeks.
Trial: 26094723
Drug: Clofazimine 100
RxNorm normalized name: clofazimine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine 100 mg t.d.s for 12 weeks, along with prednisolone 40 mg o.d. tapered over 12 weeks.
Trial: 22959555
Drug: 1-h infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h infusion of 0.5 g doripenem every 8 hours for seven doses
Trial: 22959555
Drug: 4-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-h infusion of 0.5 g doripenem every 8 hours for seven doses
Trial: 19079316
Drug: PCR-based preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCR-based preemptive therapy (group A)
Trial: 19079316
Drug: Empirical antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antifungal therapy with liposomal amphotericin B (group B)
Trial: 7745232
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon (GLU, 1 mg)
Trial: 7745232
Drug: Intravenous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous glucagon (GLU, 1 mg)
Trial: 7745232
Drug: Intravenous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous glucagon (GLU, 1 mg) with GHRH (1 microgram/kg)
Trial: 7745232
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon (GLU, 1 mg) with GHRH (1 microgram/kg)
Trial: 15361500
Drug: CDP571 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 (10 mg/kg) in patients with baseline CRP >=10 mg/l
Trial: 15361500
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in patients with baseline CRP >=10 mg/l
Trial: 9844753
Drug: melatonin 5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin 5‐mg fast‐release (FR) formulation
Trial: 9844753
Drug: melatonin 0.5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin 0.5‐mg fast‐release (FR) formulation
Trial: 9844753
Drug: melatonin 2‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin 2‐mg controlled‐release (CR) formulation
Trial: 7986000
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg, every 12 h, orally for 5 days)
Trial: 7986000
Drug: Ceftriaxone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (3 g, once daily, intravenously for 3 days)
Trial: 2658458
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg x 3
Trial: 27572548
Drug: Dexmedetomidine 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg
Trial: 23260750
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid emulsion (0.2 g/kg) over 6 h for 3 consecutive days
Trial: 18496338
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (percutaneous radiofrequency neurotomy)
Trial: 9164808
Drug: Moderate-mineral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-mineral formula (510 mg of calcium per liter and 390 mg of phosphorus per liter)
Trial: 9164808
Drug: High-mineral formula
RxNorm normalized name: Mineral Oil (high Viscosity)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-mineral formula (1350 mg of calcium per liter and 900 mg of phosphorus per liter)
Trial: 9164808
Drug: Cow milk
RxNorm normalized name: cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow milk (1230 mg of calcium per liter and 960 mg of phosphorus per liter)
Trial: 3090860
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg DSCG rectally as enemas for eight weeks
Trial: 20234364
Drug: CT+ZOL (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT+ZOL (neoadjuvant chemotherapy with zoledronic acid)
Trial: 20234364
Drug: CT (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (neoadjuvant chemotherapy)
Trial: 12655261
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg twice daily
Trial: 11185667
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 10 mg/m2
Trial: 11185667
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 30 mg/m2
Trial: 11185667
Drug: s.c. bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. bolus of 20 mg/m2
Trial: 11185667
Drug: s.c. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. administration
Trial: 11185667
Drug: s.c. dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. dosing compared to i.v. dosing
Trial: 11185667
Drug: Ribozyme administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ribozyme administration
Trial: 1492863
Drug: Dihydroergocristine (DHEC)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (DHEC) 6 mg tablet daily for four months
Trial: 2871007
Drug: Propranolol (PROP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (PROP, 160 mg/day)
Trial: 2871007
Drug: Atenolol (ATEN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (ATEN, 100 mg/day)
Trial: 9696964
Drug: Tiagabine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (4 mg three times daily for 9 days)
Trial: 9696964
Drug: Digoxin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.5 mg twice a day for 1 day, then 0.25 mg once a day for 8 days)
Trial: 9696964
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of tiagabine and digoxin
Trial: 29361433
Drug: Weekly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text message intervention for 1 year
Trial: 24723487
Drug: BEV/IRI (neo-adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEV/IRI (neo-adjuvant intravenous BEV, 10 mg/kg, and IRI, 125 mg/m², every 2 weeks for four cycles before RT; adjuvant BEV and IRI every 2 weeks for 6 months)
Trial: 24723487
Drug: Control (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (concomitant oral TMZ, 75 mg/m²/day during RT, and 150-200 mg/m² for 5 days every 28 days for 6 months)
Trial: 11378811
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (150 mg), alpha-tocopherol (75 mg), beta-carotene (15 mg), selenium (101 microg), and calcium (1.6 g)
Trial: 9218294
Drug: Carmustine-loaded polymer
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine-loaded polymer (active treatment)
Trial: 8356525
Drug: Control (existing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (existing therapy)
Trial: 29688579
Drug: Avoralstat 500
RxNorm normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoralstat 500 mg
Trial: 29688579
Drug: Avoralstat 300
RxNorm normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoralstat 300 mg
Trial: 18633043
Drug: Pudendal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal nerve block with 15 mL of ropivacaine 7.5 mg/mL
Trial: 17723130
Drug: Daily rFVIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rFVIIa prophylaxis with 90 microg kg(‐1) for 3 months
Trial: 17723130
Drug: Daily rFVIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rFVIIa prophylaxis with 270 microg kg(‐1) for 3 months
Trial: 17723130
Drug: Conventional on‐demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional on‐demand therapy
Trial: 1571118
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate (900 mg) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Trial: 1571118
Drug: Cefazolin sodium
RxNorm normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin sodium (2 g) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Trial: 11273797
Drug: Amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanic acid
Trial: 29851070
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (0.02 g kg‐1 of an association of Lactobacillus acidophilus, Enterococcus faecium, Bifidobacterium thermophilum, and Bifidobacterium longum) with K2 Cr2 O7
Trial: 29851070
Drug: K2 Cr2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K2 Cr2 O7 at doses of 0.12 g kg‐1, 0.24 g kg‐1, and 0.36 g kg‐1
Trial: 12206010
Drug: URA 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: URA 0.25 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U1)
Trial: 12206010
Drug: URA 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: URA 0.5 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U2)
Trial: 29630033
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block (ISB) with 20 mL of levobupivacaine 0.5% and epinephrine 5 μg/mL
Trial: 29630033
Drug: Small-volume supraclavicular
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-volume supraclavicular block (SCB) with 20 mL of levobupivacaine 0.5%
Trial: 27064369
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) using the novel negative pressure device (NPD)
Trial: 24216257
Drug: Oral Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Supplementation (OS)
Trial: 16054520
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5, 5 x 10(7) cfu/tablet)
Trial: 11199957
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release 300 mg/day
Trial: 9531003
Drug: Prescribed intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed intake of carbohydrate-electrolyte solution (6.9% Lucozade-Sport; sodium, 24 mmol l(‐1); potassium, 2.6 mmol l(‐1); calcium, 1.2 mmol l(‐1); osmolality, 300 mOsm kg(‐1))
Trial: 9531003
Drug: Ad libitum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad libitum intake of carbohydrate-electrolyte solution
Trial: 9531003
Drug: Prescribed intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed intake of carbohydrate-electrolyte solution
Trial: 8270977
Drug: L-PAM plus
RxNorm normalized name: L-PAM
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-PAM plus BSO
Trial: 8270977
Drug: L-PAM alone
RxNorm normalized name: L-PAM
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-PAM alone
Trial: 25492378
Drug: Sensor-augmented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented therapy
Trial: 21255828
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (1 mg/kg infusion on alternate days for 30 days, total dose 15 mg/kg)
Trial: 21255828
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B with miltefosine (single injection of 5 mg/kg liposomal amphotericin B and 7-day 50 mg oral miltefosine)
Trial: 21255828
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B with paromomycin (single 10-day 11 mg/kg intramuscular paromomycin)
Trial: 21440702
Drug: Constraint‐Induced Movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐Induced Movement Therapy (CIMT)
Trial: 10681486
Drug: triflusal 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triflusal 600 mg once daily for 35 days
Trial: 10681486
Drug: aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 300 mg once daily for 35 days
Trial: 9018764
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide (4 mg twice daily for 1 week)
Trial: 29482543
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (NSPT) with immediate ultrasonic scaling, scaling and root planning, and subgingival 10% povidone iodine irrigation.
Trial: 20046552
Drug: Manual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual treatment technique (4-minute pain-alleviating traction) at the most symptomatic zygopophyseal joint